throbber

`
`
`
`
`
`
`
`
`prolong QT. Temporarily suspend, dose reduce, or permanently
`discontinue XALKORI. (5.3)
`
`Bradycardia: XALKORI can cause bradycardia. Monitor heart rate and
`
`blood pressure regularly. Temporarily suspend, dose reduce, or
`
`permanently discontinue XALKORI. (5.4)
`Severe Visual Loss: Reported in 0.2% of patients. Discontinue
`
`loss. Perform an
`XALKORI
`in patients with severe visual
`
`
`ophthalmological evaluation. (5.5)
`
`Embryofetal Toxicity: Can cause fetal harm. Advise females of
`
`reproductive potential of the potential risk to a fetus and use of effective
`contraception. (5.6, 8.1, 8.3)
`
`
`
`------------------------------ADVERSE REACTIONS------------------------------­
`
`The most common adverse reactions (≥25%) are vision disorders, diarrhea,
`transaminases, upper
`nausea, vomiting, constipation, edema, elevated
`
`
`respiratory infection, decreased appetite, and dysgeusia. (6)
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at
`
`1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
`
`
`------------------------------DRUG INTERACTIONS------------------------------­
`
`
`CYP3A Inhibitors: Avoid concurrent use of XALKORI with strong
`
`CYP3A inhibitors. (7.1)
`CYP3A Inducers: Avoid concurrent use of XALKORI with strong
`
`CYP3A inducers. (7.2)
`CYP3A Substrates: Avoid concurrent use of XALKORI with CYP3A
`
`substrates with narrow therapeutic indices. (7.3)
`
`
`
`
`
`
`
`
`-----------------------USE IN SPECIFIC POPULATIONS-----------------------­
`
`Lactation: Do not breastfeed while taking XALKORI (8.2)

`
`
`
`See 17 for PATIENT COUNSELING INFORMATION and FDA-
`approved patient labeling.

`
`
`
`
`
`
`
`Revised: 9/2015
`
` HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`These highlights do not include all the information needed to use
`XALKORI® safely and effectively. See full prescribing information for
`
`XALKORI.
`
`XALKORI® (crizotinib) capsules, for oral use
`Initial U.S. Approval: 2011
`
`
`----------------------------RECENT MAJOR CHANGES-------------------------­
`
`Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6)
`9/2015
`
`
`----------------------------INDICATIONS AND USAGE--------------------------­
`
`XALKORI is a kinase inhibitor indicated for the treatment of patients with
`
`metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic
`lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1)
`
`
`
`
`----------------------DOSAGE AND ADMINISTRATION----------------------­
`
`
`Recommended dose: 250 mg orally, twice daily (2.2)
`
`
`Renal Impairment: 250 mg orally, once daily in patients with severe
`
`
`
`renal impairment (creatinine clearance <30 mL/min) not requiring
`dialysis. (2.2)
`
`
`
`
`
`
`
`
`
`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`
`
`1
`
`2
`
`
`---------------------DOSAGE FORMS AND STRENGTHS---------------------­
`
`Capsules: 250 mg and 200 mg (3)
`
`
`
`-------------------------------CONTRAINDICATIONS-----------------------------­
`
`None (4)
`
`
`-----------------------WARNINGS AND PRECAUTIONS-----------------------­
`
`
`
`Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.
`
`Monitor with periodic liver testing. Temporarily suspend, dose reduce,
`
`or permanently discontinue XALKORI. (5.1)
`
`Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of
`
`patients. Permanently discontinue in patients with ILD/pneumonitis.
`
`(5.2)
`QT Interval Prolongation: Occurred in 2.1% of patients. Monitor with
`
`electrocardiograms and electrolytes in patients who have a history of or
`
`
`predisposition for QTc prolongation, or who are taking medications that
`
`_______________________________________________________________________________________________________________________________________
`
`
`
`8
`
`USE IN SPECIFIC POPULATIONS
`
`8.1 Pregnancy
`
`8.2 Lactation
`8.3 Females and Males of Reproductive Potential
`8.4
` Pediatric Use
`8.5
` Geriatric Use
`8.6
` Hepatic Impairment
`8.7
` Renal Impairment
`10 OVERDOSAGE
`
`11 DESCRIPTION
`
`12 CLINICAL PHARMACOLOGY
`
`12.1 Mechanism of Action
`
`
`12.2 Pharmacodynamics
`12.3 Pharmacokinetics
`
`
`
`13 NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`14 CLINICAL STUDIES
`16 HOW SUPPLIED/STORAGE AND HANDLING
`17 PATIENT COUNSELING INFORMATION
`
`
`* Sections or subsections omitted from the full prescribing information are not
`
`listed.
`
`INDICATIONS AND USAGE
`
`DOSAGE AND ADMINISTRATION
`
`
`2.1 Patient Selection
`
`
`2.2 Recommended Dosing
`
`
`2.3 Dose Modification
`
`
`DOSAGE FORMS AND STRENGTHS
`3
`
`
`CONTRAINDICATIONS
`4
`
`
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Hepatotoxicity
`
`Interstitial Lung Disease (Pneumonitis)
`5.2
`
`5.3 QT Interval Prolongation
`
`
`5.4 Bradycardia
`
`5.5 Severe Visual Loss
`
`5.6 Embryofetal Toxicity
`
`
`ADVERSE REACTIONS
`
`
`6.1 Clinical Trials Experience
`
`DRUG INTERACTIONS
`
`
`7.1 Drugs That May Increase Crizotinib Plasma Concentrations
`
`
`7.2 Drugs That May Decrease Crizotinib Plasma Concentrations
`
`
`
`7.3 Drugs Whose Plasma Concentrations May Be Altered By
`
`Crizotinib
`_______________________________________________________________________________________________________________________________________
`
`
`
`6
`
`
`7
`
`Reference ID: 3819612
`
`1
`
`
`

`

`
`
` INDICATIONS AND USAGE
`
`FULL PRESCRIBING INFORMATION
`
`1
`
`XALKORI is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose
`tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
`
`2
`
`
`
`DOSAGE AND ADMINISTRATION
`
`
`2.1 Patient Selection
`
`Select patients for the treatment of metastatic NSCLC with XALKORI based on the presence of ALK positivity
`in tumor specimens [see Indications and Usage (1) and Clinical Studies (14)]. Information on FDA-approved
`tests for the detection of ALK rearrangements in NSCLC is available at
` http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.
`
`2.2 Recommended Dosing
`
`The recommended dose of XALKORI is 250 mg orally, twice daily until disease progression or no longer
`tolerated by the patient. The recommended dose of XALKORI in patients with severe renal impairment
`(creatinine clearance <30 mL/min) not requiring dialysis is 250 mg orally, once daily [see Use in Specific
`Populations (8.7) and Clinical Pharmacology (12.3)].
`
`XALKORI may be taken with or without food. Swallow capsules whole. If a dose of XALKORI is missed,
`make up that dose unless the next dose is due within 6 hours. If vomiting occurs after taking a dose of
`XALKORI, take the next dose at the regular time.
`
`2.3 Dose Modification
`
`Reduce dose as below, if one or more dose reductions are necessary due to adverse reactions of Grade 3 or 4
`severity, as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0:
`
` First dose reduction: XALKORI 200 mg taken orally twice daily
`
` Second dose reduction: XALKORI 250 mg taken orally once daily
`
` Permanently discontinue if unable to tolerate XALKORI 250 mg taken once daily
`
`
`Dose reduction guidelines are provided in Tables 1 and 2.
`
`
`
`
`CTCAE Grade
`Grade 3
`
`Grade 4
`
` Table 1. XALKORI Dose Modification – Hematologic Toxicitiesa
`XALKORI Dosing
`
`Withhold until recovery to Grade 2 or less, then resume at the same dose schedule
`
`
`Withhold until recovery to Grade 2 or less, then resume at next lower dose
`
`a Except lymphopenia (unless associated with clinical events, e.g., opportunistic infections).
`
`
`Reference ID: 3819612
`
`2
`
`
`

`

`
`
` Table 2. XALKORI Dose Modification – Non-Hematologic Toxicities
`XALKORI Dosing
`
`Withhold until recovery to baseline or less than or equal to 3 times
`
`ULN, then resume at reduced dose
`
`Criteria
`Alanine aminotransferase (ALT) or aspartate
`aminotransferase (AST) elevation greater
`than 5 times upper limit of normal (ULN)
`with total bilirubin less than or equal to
`1.5 times ULN
`ALT or AST elevation greater than 3 times
`ULN with concurrent total bilirubin elevation
`greater than 1.5 times ULN (in the absence
`of cholestasis or hemolysis)
`Any Grade drug-related interstitial lung
`disease/pneumonitis
`QTc greater than 500 ms on at least
`2 separate ECGs
`
`
`QTc greater than 500 ms or greater than or
`equal to 60 ms change from baseline with
`Torsade de pointes or polymorphic
`ventricular tachycardia or signs/symptoms of
`serious arrhythmia
`
` Bradycardiaa (symptomatic, may be severe
`and medically significant, medical
`intervention indicated)
`
`Permanently discontinue
`
`
`Permanently discontinue
`
`
`Withhold until recovery to baseline or to a QTc less than 481 ms,
`
`
`then resume at reduced dose
`
`Permanently discontinue
`
`
`
` Withhold until recovery to asymptomatic bradycardia or to a heart
`
`rate of 60 bpm or above
`
`Evaluate concomitant medications known to cause bradycardia, as
`
`well as anti-hypertensive medications
`
`If contributing concomitant medication is identified and
`discontinued, or its dose is adjusted, resume at previous dose upon
`
`recovery to asymptomatic bradycardia or to a heart rate of 60 bpm
`
`or above
`
`If no contributing concomitant medication is identified, or if
`contributing concomitant medications are not discontinued or dose
`modified, resume at reduced dose upon recovery to asymptomatic
`
`
`bradycardia or to a heart rate of 60 bpm or above
`
`Bradycardiaa,b (life-threatening
`
`consequences, urgent intervention indicated)
`
`Permanently discontinue if no contributing concomitant medication
`
`is identified
`
`If contributing concomitant medication is identified and
`discontinued, or its dose is adjusted, resume at 250 mg once daily
`
`upon recovery to asymptomatic bradycardia or to a heart rate of
`60 bpm or above, with frequent monitoring
`
`
`Visual Loss (Grade 4 Ocular Disorder)
`
`
`Discontinue during evaluation of severe vision loss
`
`
`a Heart rate less than 60 beats per minute (bpm).
`
`
`
`b Permanently discontinue for recurrence.
`
`
`
`
`
`Monitor complete blood counts including differential white blood cell counts monthly and as clinically
` indicated, with more frequent repeat testing if Grade 3 or 4 abnormalities are observed, or if fever or infection
`occurs.
`
`
`Reference ID: 3819612
`
`3
`
`

`

`3
`
`DOSAGE FORMS AND STRENGTHS
`
`250 mg capsules
`
`
`Hard gelatin capsule, size 0, pink opaque cap and body, with “Pfizer” on the cap and “CRZ 250” on the body.
`
`
`200 mg capsules
`
`
`Hard gelatin capsule, size 1, white opaque body and pink opaque cap, with “Pfizer” on the cap and “CRZ 200”
`
`on the body.
`
`
`CONTRAINDICATIONS
`
`
`
`4
`
`None
`
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Hepatotoxicity
`
`Drug-induced hepatotoxicity with fatal outcome occurred in 2 (0.1%) of the 1669 patients treated with
`XALKORI across clinical trials in patients with NSCLC. Concurrent elevations in alanine aminotransferase
`(ALT) or aspartate aminotransferase (AST) greater than or equal to three times the upper limit of normal (ULN)
`and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 10
`
`patients (0.6%) treated with XALKORI. Additionally, elevations in ALT or AST greater than five times the
`ULN occurred in 184 (11%) and 93 (5.7%) patients, respectively. Seventeen patients (1.0%) required permanent
`discontinuation due to elevated transaminases. Transaminase elevations generally occurred within the first
`
`2 months of treatment.
`
`Monitor with liver function tests including ALT and total bilirubin every 2 weeks during the first 2 months of
`
`treatment, then once a month and as clinically indicated, with more frequent repeat testing for increased liver
`transaminases, alkaline phosphatase, or total bilirubin in patients who develop transaminase elevations.
`Temporarily suspend, dose reduce, or permanently discontinue XALKORI as described in Table 2 [see Dosage
`and Administration (2.3) and Adverse Reactions (6)].
`
`5.2 Interstitial Lung Disease (Pneumonitis)
`
`Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with
`XALKORI. Across clinical trials (n=1669), 49 XALKORI-treated patients (2.9%) had ILD of any grade,
`18 patients (1.1%) had Grade 3 or 4 ILD, and 8 patients (0.5%) had fatal ILD. These cases generally occurred
`within 3 months after the initiation of XALKORI.
`
`
`Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis. Exclude other potential causes of
`ILD/pneumonitis, and permanently discontinue XALKORI in patients diagnosed with drug-related
`ILD/pneumonitis [see Dosage and Administration (2.3) and Adverse Reactions (6)].
`
`
`Reference ID: 3819612
`
`4
`
`
`

`

`5.3 QT Interval Prolongation
`
`QTc prolongation can occur in patients treated with XALKORI. Across clinical trials, 32 of 1560 patients
`(2.1%) had QTcF (corrected QT by the Fridericia method) greater than or equal to 500 ms and 76 of 1520
`patients (5.0%) had an increase from baseline QTcF greater than or equal to 60 ms by automated machine-read
`evaluation of ECG.
`
`
`Avoid use of XALKORI in patients with congenital long QT syndrome. Consider periodic monitoring with
`electrocardiograms (ECGs) and electrolytes in patients with congestive heart failure, bradyarrhythmias,
`electrolyte abnormalities, or who are taking medications that are known to prolong the QT interval.
`Permanently discontinue XALKORI in patients who develop QTc greater than 500 ms or greater than or equal
`to 60 ms change from baseline with Torsade de pointes or polymorphic ventricular tachycardia or
`signs/symptoms of serious arrhythmia. Withhold XALKORI in patients who develop QTc greater than 500 ms
`
`on at least 2 separate ECGs until recovery to a QTc less than or equal to 480 ms, then resume XALKORI at a
`reduced dose as described in Table 2 [see Dosage and Administration (2.3) and Clinical Pharmacology (12.2)].
`
`5.4 Bradycardia
`
`Symptomatic bradycardia can occur in patients receiving XALKORI. Across clinical trials, bradycardia
`occurred in 205 (12.3%) of 1669 patients treated with XALKORI. A total of 242 (14.9%) patients had a heart
`rate less than 50 beats per minute. In Studies 1 and 2, Grade 3 syncope occurred in 2.0% of XALKORI-treated
`patients and in 0.6% of the chemotherapy-treated patients.
`
`
`Avoid using XALKORI in combination with other agents known to cause bradycardia (e.g., beta-blockers,
`non-dihydropyridine calcium channel blockers, clonidine and digoxin) to the extent possible. Monitor heart rate
`and blood pressure regularly. In cases of symptomatic bradycardia that is not life-threatening, hold XALKORI
`until recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above, re-evaluate the use of
`concomitant medications, and adjust the dose of XALKORI. Permanently discontinue for life-threatening
`bradycardia due to XALKORI; however, if associated with concomitant medications known to cause
`bradycardia or hypotension, hold XALKORI until recovery to asymptomatic bradycardia or to a heart rate of
`
`60 bpm or above, and if concomitant medications can be adjusted or discontinued, restart XALKORI at 250 mg
`once daily with frequent monitoring [see Dosage and Administration (2.3) and Adverse Reactions (6)].
`
`5.5 Severe Visual Loss
`
`Across all clinical trials, the incidence of Grade 4 visual field defect with vision loss was 0.2% (4/1669). Optic
`atrophy and optic nerve disorder have been reported as potential causes of vision loss.
`
`Discontinue XALKORI in patients with new onset of severe visual loss (best corrected vision less than 20/200
`in one or both eyes). Perform an ophthalmological evaluation consisting of best corrected visual acuity, retinal
`photographs, visual fields, optical coherence tomography (OCT) and other evaluations as appropriate for new
`onset of severe visual loss. There is insufficient information to characterize the risks of resumption of
`XALKORI in patients with a severe visual loss; a decision to resume XALKORI should consider the potential
`benefits to the patient.
`
`
`5.6 Embryofetal Toxicity
`
`Based on its mechanism of action, XALKORI can cause fetal harm when administered to a pregnant woman. In
`animal reproduction studies, oral administration of crizotinib in pregnant rats during organogenesis at exposures
`similar to those observed with the maximum recommended human dose resulted in embryotoxicity and
`fetotoxicity. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to
`5
`
`
`Reference ID: 3819612
`
`

`

`
`
` ADVERSE REACTIONS
`
`use effective contraception during treatment with XALKORI and for at least 45 days following the final dose
`[see Use in Specific Populations (8.1, 8.3)].
`
`6
`
`The following adverse reactions are discussed in greater detail in other sections of the labeling:
`
` Hepatotoxicity [see Warnings and Precautions (5.1)]
`
`
`Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.2)]
`
`
`
` QT Interval Prolongation [see Warnings and Precautions (5.3)]
`
`
` Bradycardia [see Warnings and Precautions (5.4)]
`
`
` Severe Visual Loss [see Warnings and Precautions (5.5)]
`
`
`
`
`
`6.1 Clinical Trials Experience
`
`Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the
`clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not
`
` reflect the rates observed in clinical practice.
`
`The safety of XALKORI is based primarily on 343 patients with ALK-positive metastatic NSCLC who
`received XALKORI 250 mg twice daily in two open-label, randomized, active-controlled trials (Studies 1
`and 2). This is supplemented with information on adverse drug reactions in 1326 patients with ALK-positive
`metastatic NSCLC who received XALKORI 250 mg twice daily across clinical trials, for a total of 1669
`
`patients across all clinical studies.
`
`The most common adverse reactions (≥25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea,
`nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite,
`and dysgeusia.
`
`Previously Untreated ALK-Positive Metastatic NSCLC - Study 1
`
`
`The data in Table 3 are derived from 340 patients with ALK-positive metastatic NSCLC who had not received
`previous systemic treatment for advanced disease who received treatment in a randomized, multicenter, open-
`
`label, active-controlled trial (Study 1). Patients in the XALKORI arm (n=171) received XALKORI 250 mg
`orally twice daily until documented disease progression, intolerance to therapy, or the investigator determined
`
`that the patient was no longer experiencing clinical benefit. A total of 169 patients in the chemotherapy arm
`received pemetrexed 500 mg/m2 in combination with cisplatin 75 mg/m2 (n=91) or carboplatin at a dose
`calculated to produce an area under the concentration-time curve (AUC) of 5 or 6 mg·min/mL (n=78).
`Chemotherapy was given by intravenous infusion every 3 weeks for up to 6 cycles, in the absence of dose-
`limiting chemotherapy-related toxicities. After 6 cycles, patients remained on study with no additional
`anticancer treatment, and tumor assessments continued until documented disease progression.
`
`The median duration of study treatment was 10.9 months for patients in the XALKORI arm and 4.1 months for
`patients in the chemotherapy arm. Median duration of treatment was 5.2 months for patients who received
`XALKORI after cross over from chemotherapy. Across the 340 patients who were treated in Study 1, the
`median age was 53 years; 16% of patients were older than 65 years. A total of 62% of patients were female and
`
` 46% were Asian.
`
`Serious adverse events were reported in 58 patients (34%) treated with XALKORI. The most frequent serious
`
`adverse events reported in patients treated with XALKORI were dyspnea (4.1%) and pulmonary embolism
`(2.9%). Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic
`shock, acute respiratory failure, and diabetic ketoacidosis.
`6
`
`Reference ID: 3819612
`
`

`

`
`Dose reductions due to adverse reactions were required in 6.4% of XALKORI-treated patients. The most
`frequent adverse reactions that led to dose reduction in these patients were nausea (1.8%) and elevated
`
` transaminases (1.8%).
`
`Permanent discontinuation of XALKORI treatment for adverse reactions was 8.2%. The most frequent adverse
`reactions that led to permanent discontinuation in XALKORI-treated patients were elevated
`
` transaminases (1.2%), hepatotoxicity (1.2%), and ILD (1.2%).
`
`Tables 3 and 4 summarize common adverse reactions and laboratory abnormalities in XALKORI-treated
`
` patients.
`
`Table 3. Adverse Reactions Reported at a Higher Incidence (≥5% Higher for All Grades or ≥2% Higher
`for Grades 3/4) with XALKORI than Chemotherapy in Study 1
`
`XALKORI
`Adverse Reaction
`
`(N=171)
`
`Chemotherapy (Pemetrexed/Cisplatin
`or Pemetrexed/Carboplatin)
`(N=169)
`All Grades
`Grade 3/4
`(%)
`(%)
`
`
`2
`0
`1
`0
`
`
`
`10
`0
`
`
`3
`36
`
`1
`13
`
`0
`30
`
`0
`2
`1
`2
`0
`12
`
`
`
`
`
`12
`1
`
`11
`1
`
`
`
`
`12
`1
`
`
`2
`0
`
`
`
`
`7
`0
`2
`1
`
`
`
`10
`1
`5
`0
`
`15
`0
`
`Cardiac Disorders
`
` Electrocardiogram QT prolonged
`
`
` Bradycardiaa
`
`Eye Disorders
`
` Vision disorderb
`
`Gastrointestinal Disorders
` Vomiting
`Diarrhea
`Constipation
` Dyspepsia
`
` Dysphagia
` Abdominal painc
`General Disorders and
`Administration Site Conditions
`Edemad
` Pyrexia
`Infections and Infestations
` Upper respiratory infectione
`
`Investigations
`Weight increased
`
`Musculoskeletal and Connective
`Tissue Disorders
`
`
`Pain in extremity
` Muscle spasm
`Nervous System Disorder
`
`Dizzinessf
`
`
`
` Dysgeusia
`
` Headache
` Includes cases reported within the clustered terms:
`
`
`a Bradycardia (Bradycardia, Sinus bradycardia)
`
`
`
`b Vision Disorder (Diplopia, Photophobia, Photopsia, Visual acuity reduced, Vision blurred, Vitreous floaters, Visual impairment)
`
`
`
`
`
`
`
`c Abdominal pain (Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Abdominal tenderness)
`
`
`
`d Edema (Edema, Edema peripheral, Face edema, Generalised edema, Local swelling, Periorbital edema)
`
`e Upper respiratory infection (Nasopharyngitis, Pharyngitis, Rhinitis, Upper respiratory tract infection)
`
`
`f Dizziness (Balance disorder, Dizziness, Dizziness postural, Presyncope)
`
`
`7
`
`Grade 3/4
`(%)
`
`2
`1
`
`1
`
`2
`2
`2
`0
`1
`0
`
`
`1
`0
`
`0
`
`1
`
`
`0
`0
`
`0
`0
`1
`
`All Grades
`(%)
`
`6
`
`14
`
`
`71
`
`46
`
`61
`
`43
`
`14
`
`10
`
`26
`
`
`
`49
`
`19
`
`
`
`32
`
`8
`
`
`16
`
`8
`
`
`18
`
`26
`
`22
`
`
`
`Reference ID: 3819612
`
`

`

`
`Additional adverse reactions occurring at an overall incidence between 1% and 60% in patients treated with
`XALKORI included nausea (56%), decreased appetite (30%), fatigue (29%), neuropathy (21%; which included
`gait disturbance, hypoaesthesia, muscular weakness, neuralgia, neuropathy peripheral, paraesthesia, peripheral
`sensory neuropathy, polyneuropathy, sensory disturbance), rash (11%), renal cyst (5%), ILD (1%; ILD,
`pneumonitis), and syncope (1%).
`
`Table 4. Summary of Treatment-Emergent Laboratory Abnormalities with Grade 3 or 4 Incidence of
`≥4% in XALKORI-Treated Patients in Study 1
`
` XALKORI
`Grade 3/4
`Any Grade
`(%)
`(%)
`
`
`52
`11
`
`
`48
`7
`
`
`
`79
`15
`
`
`66
`8
`
`32
`10
`
`
`
`Chemotherapy
`Any Grade
`Grade 3/4
`(%)
`(%)
`
`
`59
`16
`
`
`53
`13
`
`
`
`
`33
`2
`
`28
`1
`
`21
`6
`
`
`Laboratory Abnormality
`
`
`Hematology
`
`Neutropenia
`Lymphopenia
`Chemistry
`
`ALT elevation
`AST elevation
`Hypophosphatemia
`
`
`Previously Treated ALK-Positive Metastatic NSCLC - Study 2
`
`The data in Table 5 are derived from 343 patients with ALK-positive metastatic NSCLC enrolled in a
`randomized, multicenter, active-controlled, open-label trial (Study 2). Patients in the XALKORI arm (n=172)
`received XALKORI 250 mg orally twice daily until documented disease progression, intolerance to therapy, or
`the investigator determined that the patient was no longer experiencing clinical benefit. A total of 171 patients
`in the chemotherapy arm received pemetrexed 500 mg/m2 (n=99) or docetaxel 75 mg/m2 (n=72) by intravenous
`infusion every three weeks until documented disease progression, intolerance to therapy, or the investigator
`
` determined that the patient was no longer experiencing clinical benefit. Patients in the chemotherapy arm
`received pemetrexed unless they had received pemetrexed as part of first-line or maintenance treatment.
`
`The median duration of study treatment was 7.1 months for patients who received XALKORI and 2.8 months
`
` for patients who received chemotherapy. Across the 347 patients who were randomized to study treatment
`(343 received at least one dose of study treatment), the median age was 50 years; 14% of patients were older
`than 65 years. A total of 56% of patients were female and 45% of patients were Asian.
`
`Serious adverse reactions were reported in 64 patients (37.2%) treated with XALKORI and 40 patients (23.4%)
`in the chemotherapy arm. The most frequent serious adverse reactions reported in patients treated with
`XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%). Fatal
`adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute
`respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD,
`respiratory failure and sepsis.
`
`Dose reductions due to adverse reactions were required in 16% of XALKORI-treated patients. The most
`frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were alanine
`aminotransferase (ALT) elevation (7.6%) including some patients with concurrent aspartate aminotransferase
`(AST) elevation, QTc prolongation (2.9%), and neutropenia (2.3%).
`
`XALKORI was discontinued for adverse reactions in 15% of patients. The most frequent adverse reactions that
`led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and
`pulmonary embolism (1.2%).
`
`
`Reference ID: 3819612
`
`8
`
`
`

`

`Adverse Reaction
`
`
`
`
`Tables 5 and 6 summarize common adverse reactions and laboratory abnormalities in XALKORI-treated
`patients.
`
`
`Table 5. Adverse Reactions Reported at a Higher Incidence (≥5% Higher for All Grades or ≥2% Higher
`for Grades 3/4) with XALKORI than Chemotherapy in Study 2
`
`XALKORI
`Chemotherapy
`(N=172)
`(Pemetrexed or Docetaxel)
`(N=171)
`All Grades
`Grade 3/4
`(%)
`(%)
`
`
`8
`0
`9
`0
`0
`0
`
`
`9
`0
`
`
`0
`0
`0
`0
`
`
`4
`0
`
`
`
`18
`0
`
`37
`1
`
`19
`1
`
`23
`0
`3
`0
`
`
`
`13
`1
`
`
`
`
`2
`2
`
`
`
`
`
`16
`0
`
`All Grades
`(%)
`
`
`22
`
`26
`3
`
`60
`
`
`5
`5
`
`10
`
`
`
`47
`
`55
`
`60
`
`42
`8
`
`
`26
`
`
`6
`
`
`
`31
`
`Grade 3/4
`(%)
`
`1
`0
`3
`
`0
`
`3
`0
`
`1
`
`1
`1
`0
`2
`0
`
`0
`
`
`5
`
`
`0
`
`Nervous System Disorder
` Dizzinessa
`
`
`Dysgeusia
`
` Syncope
`Eye Disorders
`
` Vision disorderb
`
`
`Cardiac Disorders
`
`
` Electrocardiogram QT prolonged
` Bradycardiac
`
`Investigations
`Weight decreased
`
`Gastrointestinal Disorders
` Vomiting
`Nausea
`
` Diarrhea
`Constipation
` Dyspepsia
`
`Infections and Infestations
` Upper respiratory infectiond
`
`Respiratory, Thoracic and
`
`Mediastinal Disorders
`Pulmonary embolisme
`
`General Disorders and
`Administration Site Conditions
`Edemaf
` Includes cases reported within the clustered terms:
`
`
`
`a Dizziness (Balance disorder, Dizziness, Dizziness postural)
`
`b Vision Disorder (Diplopia, Photophobia, Photopsia, Vision blurred, Visual acuity reduced, Visual impairment, Vitreous floaters)
`
`
`
`c Bradycardia (Bradycardia, Sinus bradycardia)
`
`
`
`d Upper respiratory infection (Laryngitis, Nasopharyngitis, Pharyngitis, Rhinitis, Upper respiratory tract infection)
`
`
`e Pulmonary embolism (Pulmonary artery thrombosis, Pulmonary embolism)
`
`
`
`f Edema (Face edema, Generalized edema, Local swelling, Localized edema, Edema, Edema peripheral, Periorbital edema)
`
`
`Additional adverse reactions occurring at an overall incidence between 1% and 30% in patients treated with
`XALKORI included (%), fatigue (27%), neuropathy (19%; dysesthesia, gait disturbance, hypoesthesia,
`muscular weakness, neuralgia, peripheral neuropathy, parasthesia, peripheral sensory neuropathy,
`polyneuropathy, burning sensation in skin), rash (9%), ILD (4%; acute respiratory distress syndrome, ILD,
`
`pneumonitis), renal cyst (4%), and hepatic failure (1%).
`
`
`Reference ID: 3819612
`
`9
`
`
`

`

`Table 6. Summary of Treatment-Emergent Laboratory Abnormalities with Grade 3 or 4 Incidence of
`≥4% in XALKORI-Treated Patients in Study 2
`
` XALKORI
`Grade 3/4
`Any Grade
`(%)
`(%)
`
`
`
`
`49
`12
`
`51
`9
`
`
`
`
`76
`17
`
`61
`9
`
`18
`4
`
`28
`5
`
`Laboratory Abnormality
`
`
`
`Hematology
`Neutropenia
`Lymphopenia
`
`Chemistry
`ALT elevation
`AST elevation
`Hypokalemia
`Hypophosphatemia
`
`Chemotherapy
`Any Grade
`Grade 3/4
`(%)
`(%)
`
`
`
`
`28
`12
`
`
`60
`25
`
`
`
`38
`4
`
`33
`0
`
`10
`1
`
`25
`6
`
`
`Description of Selected Adverse Drug Reactions
`
` Vision disorders
`
`Vision disorders, most commonly visual impairment, photopsia, blurred vision, or vitreous floaters, occurred in
`1038 (62%) of 1669 patients. The majority (95%) of these patients had Grade 1 visual adverse reactions. There
`were 13 (0.8%) patients with Grade 3 and 4 (0.2%) patients with Grade 4 visual impairment.
`
`Based on the Visual Symptom Assessment Questionnaire (VSAQ-ALK), patients treated with XALKORI in
`Studies 1 and 2 reported a higher incidence of visual disturbances compared to patients treated with
`chemotherapy. The onset of vision disorder generally was within the first week of drug administration. The
`majority of patients on the XALKORI arms in Studies 1 and 2 (>50%) reported visual disturbances which
`occurred at a frequency of 4-7 days each week, lasted up to 1 minute, and had mild or no impact (scores 0 to 3
`out of a maximum score of 10) on daily activities as captured in the VSAQ-ALK questionnaire.
`
`Neuropathy
`Neuropathy, most commonly sensory in nature, occurred in 419 (25%) of 1669 patients. Most events (95%)
`were Grade 1 or Grade 2 in severity.
`
`Renal Cysts
`
`
`Renal cysts were experienced by 50 (3%) of 1669 patients. Renal cysts occurred in 8 (5%) patients treated with
`XALKORI and 1 (1%) patient treated with chemotherapy in Study 1. Renal cysts occurred in 8 (5%) patients
`
`treated with XALKORI and 1 (1%) patient treated with chemotherapy in Study 2. The majority of renal cysts in
`XALKORI-treated patients were complex. Local cystic invasion beyond the kidney occurred, in some cases
`with imaging characteristics suggestive of abscess formation. However, across clinical trials no renal abscesses
`were confirmed by microbiology tests.
`
`7
`
`7.1 Drugs That May Increase Crizotinib Plasma Concentrations
`
`
`Coadministration of crizotinib with strong CYP3A inhibitors increases crizotinib plasma concentrations [see
`Clinical Pharmacology (12.3)]. Avoid concomitant use of strong CYP3A inhibitors, including but not limited to
`atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir,
`
`telithromycin, troleandomycin, and voriconazole. Avoid grapefruit or grapefruit juice which may also increase
`plasma concentrations of crizotinib. Exercise caution with concomitant use of moderate CYP3A inhibitors.
`
`
`
`DRUG INTERACTIONS
`
`Reference ID: 3819612
`
`
`
` 10
`
`
`

`

`
`
`7.2 Drugs That May Decrease Crizotinib Plasma Concentrations
`
`Coadministration of crizotinib with strong CYP3A inducers decreases crizotinib plasma concentrations [see
`Clinical Pharmacology (12.3)]. Avoid concomitant use of strong CYP3A inducers, including but not limited to
`carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John’s Wort.
`
`7.3 Drugs Whose Plasma Concentrations May Be Altered By Crizotinib
`
`Crizotinib inhibits CYP3A both in vitro and in vivo [see Clinical Pharmacology (12.3)]. Avoid concomitant use
`
`of CYP3A substrates with narrow therapeutic range, including but not limited to alfentanil, cyclosporine,
`dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus in patients taking
`XALKORI. If concomitant use of these CYP3A substrates with narrow therapeutic range is required in patients
`taking XALKORI, dose reductions of the CYP3A substrates may be required due to adverse reactions.
`
`
`USE IN SPECIFIC POPULATIONS
`
`8
`
`8.1 Pregnancy
`
`Risk Summary
`
`Based on its mechanism of action, XALKORI

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket